Cart
sales@molnova.com
CYM 50358 hydrochloride (1314212-39-9 free base)
CAS No. 1781750-72-8
CYM 50358 hydrochloride (1314212-39-9 free base)( —— )
Catalog No. M34064 CAS No. 1781750-72-8
CYM50358 HCl is an S1P4 antagonist.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 177 | In Stock |
|
| 10MG | 247 | In Stock |
|
| 25MG | 392 | In Stock |
|
| 50MG | 520 | In Stock |
|
| 100MG | 697 | In Stock |
|
| 200MG | 930 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCYM 50358 hydrochloride (1314212-39-9 free base)
-
NoteResearch use only, not for human use.
-
Brief DescriptionCYM50358 HCl is an S1P4 antagonist.
-
DescriptionCYM50358 hydrochloride (compound 4v) is a potent, selective sphingosine-1-phosphate 4 (S1P4) receptor antagonist. CYM50358 hydrochloride can be used in the study of influenza infection.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1781750-72-8
-
Formula Weight425.73
-
Molecular FormulaC20H19Cl3N2O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCl.Cc1cc(CN)cc(C)c1NC(=O)c1ccc(o1)-c1cc(Cl)ccc1Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Guerrero M, et al. Discovery, design and synthesis of the first reported potent and selective sphingosine-1-phosphate 4 (S1P4) receptor antagonists. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3632-6.?
molnova catalog
related products
-
ecMetAP-IN-1
ecMetAP-IN-1 can be used as a QSAR model to study methionine aminopeptidase inhibitor as an anticancer agent using multiple linear regression.
-
Bragsin2
Bragsin2 is a hydration-resistant cell penetrant, selective and non-competitive inhibitor of Afr guanine nucleotide exchange factor BRAG2.
-
4A3-SC8
4A3-SC8 is a modular dendritic macromolecule with cationic and lipophilic groups that enables small RNAs to prolong survival in an aggressive hepatocellular carcinoma model and can be used to synthesize lipid nanoparticles.
